All Stories

  1. Primary headache in SLE –systematic review and meta-analysis
  2. Impact of baseline proteinuria level on long-term outcomes in lupus nephritis
  3. Evaluation of Progression From Preclinical to Systemic Autoimmune Rheumatic Disease: Novel Use of the European Alliance of Associations for Rheumatology/American College of Rheumatology Systemic Lupus Erythematosus Classification Criteria as...
  4. Short and Long-Term Outcomes of Patients with Pure Membranous Lupus Nephritis Compared to Patients with Proliferative Disease
  5. Modelling long-term outcomes for patients with systemic lupus erythematosus
  6. Unfavorable Outcomes Associated With Glucocorticoid Use in Current Standard‐of‐Care Management of Systemic Lupus Erythematosus in Canada
  7. Circulating neutrophil extracellular trap remnants as a biomarker to predict outcomes in lupus nephritis
  8. Different Immunologic Profiles are Associated with Distinct Clinical Phenotypes in Longitudinally Followed Systemic Lupus Erythematosus Patients
  9. More Evidence on the Validity of the Measurement Properties of PROMIS Computerized Adaptive Tests in Systemic Lupus Erythematosus
  10. Measuring treatment outcomes and change in disease activity in giant cell arteritis: a systematic literature review informing the development of the EULAR-ACR response criteria on behalf of the EULAR-ACR response criteria in giant cell arteritis task f...
  11. Correspondence on “relationship between the EULAR/ACR classification criteria and organ damage in systemic lupus erythematosus” by Chi Chiu Mok et al
  12. Genetics of longitudinal kidney function in children and adults with systemic lupus erythematosus
  13. Updating the core domains set in Systemic Lupus Erythematosus: Work planned by the Systemic Lupus Erythematosus OMERACT working group
  14. What is a response in randomised controlled trials in giant cell arteritis?
  15. Meeting report: the ALPHA project: a stakeholder meeting on lupus clinical trial outcome measures and the patient perspective
  16. Intraindividual Change in Cognitive Function Among Adults With Systemic Lupus Erythematosus: A Markov Analysis Over 7 Years
  17. Genetics of Osteonecrosis in Children and Adults with Systemic Lupus Erythematosus
  18. Systemic lupus erythematosus phenotypes formed from machine learning with a specific focus on cognitive impairment
  19. Evaluating the Threshold Score for Classification of Systemic Lupus Erythematosus Using the EULAR/ACR Criteria
  20. A Review of Lupus Nephritis
  21. Altered Balance of Pro-Inflammatory Immune Cells to T Regulatory Cells Differentiates Symptomatic From Asymptomatic Individuals With Anti-Nuclear Antibodies
  22. Trajectories of depressive symptoms in systemic lupus erythematosus over time
  23. Physician Global Assessment International Standardisation COnsensus in Systemic Lupus Erythematosus: the PISCOS study
  24. Identification and Validation of a Urinary Biomarker Panel to Accurately Diagnose and Predict Response to Therapy in Lupus Nephritis
  25. COVID-19 Hospitalizations, Intensive Care Unit Stays, Ventilation, and Death Among Patients With Immune-mediated Inflammatory Diseases Compared to Controls
  26. What are the domains and outcome measures used in the existing neuropsychiatric systemic lupus erythematosus literature?
  27. Herpes zoster in SLE: prevalence, incidence and risk factors
  28. Validation of the automated neuropsychological assessment metrics for assessing cognitive impairment in systemic lupus erythematosus
  29. Neuropsychiatric Systemic Lupus Erythematosus in Older Adults: Diagnosis and Management
  30. Longitudinal relationships between cognitive domains and depression and anxiety symptoms in systemic lupus erythematosus
  31. The evolution of instrument selection for inclusion in core outcome sets at OMERACT: Filter 2.2
  32. Validity and reliability of patient reported outcomes measurement information system computerized adaptive tests in systemic lupus erythematous
  33. Insight into intraindividual variability across neuropsychological tests and its association with cognitive dysfunction in patients with lupus
  34. Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study
  35. Understanding COVID‐19 Risk in Patients with Immune Mediated Inflammatory Diseases: A Population‐based analysis of SARS‐CoV‐2 Testing
  36. Response to: Correspondence on “New EULAR/ACR 2019 SLE classification criteria: defining ominosity in SLE” by Whittall Garcia et al
  37. Metrics and definitions used in the assessment of cognitive impairment in systemic lupus erythematosus: A systematic review
  38. Systemic Lupus Erythematosus: The Next Generation of Ideas and Scientists
  39. Cognitive impairment in systemic lupus erythematosus is negatively related to social role participation and quality of life: A systematic review
  40. WHAT ARE THE DOMAINS AND OUTCOME MEASURES USED IN THE EXISTING NEUROPSYCHIATRIC SYSTEMATIC LUPUS ERYTHEMATOSUS LITERATURE?
  41. Serological abnormalities that predict progression to systemic autoimmune rheumatic diseases in antinuclear antibody–positive individuals
  42. Consideration of Fibromyalgia in the Assessment and Treatment of SLE
  43. Endorsement of the domains of knee and hip osteoarthritis (OA) flare: A report from the OMERACT 2020 inaugural virtual consensus vote from the flares in OA working group
  44. Systemic Lupus Erythematosus Outcome Measures for Systemic Lupus Erythematosus Clinical Trials
  45. POS0050 ARE PATIENTS WITH IMMUNE MEDIATED INFLAMMATORY DISEASES (IMID) MORE LIKELY TO RECEIVE COVID-19 TESTS AND TEST POSITIVE FOR SARS-COV-2? A MATCHED POPULATION-BASED STUDY
  46. OP0285 COVID-19 HOSPITALIZATIONS, ICU ADMISSION, AND DEATH AMONG PATIENTS WITH IMMUNE MEDIATED INFLAMMATORY DISEASES (IMID) – A POPULATION-BASED STUDY
  47. Assessment of cardiovascular risk tools as predictors of cardiovascular disease events in systemic lupus erythematosus
  48. P160 Clinical and sociodemographic associates of depression and anxiety in SLE
  49. Comment on: Association between depression and anxiety with skin and musculoskeletal clinical phenotypes in systemic lupus erythematosus: reply
  50. European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance
  51. The baseline interferon signature predicts disease severity over the subsequent 5 years in systemic lupus erythematosus
  52. New EULAR/ACR 2019 SLE Classification Criteria: defining ominosity in SLE
  53. Dual trajectories of fatigue and disease activity in an inception cohort of adults with systemic lupus erythematosus over 10 years
  54. Transfer from Pediatric to Adult Care Is Hardly Child’s Play
  55. Systemic lupus erythematosus symptom clusters and their association with patient‐reported outcomes and treatment: Analysis of real‐world data
  56. Exploring the Mental Health Needs of Persons With Autoimmune Diseases During the Coronavirus Disease 2019 Pandemic: A Proposed Framework for Future Research and Clinical Care
  57. Validity Evidence for the Use of Automated Neuropsychologic Assessment Metrics As a Screening Tool for Cognitive Impairment in Systemic Lupus Erythematosus
  58. Real-World Effectiveness of Belimumab in the Treatment of Systemic Lupus Erythematosus: Pooled Analysis of Multi-Country Data from the OBSErve Studies
  59. Measures of Anxiety in Rheumatic Diseases
  60. Measures of Cognition in Rheumatic Diseases
  61. Response to reviewer
  62. Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities
  63. Cognitive function trajectories are associated with the depressive symptoms trajectories in systemic lupus erythematosus over time
  64. Measurement properties of selected patient-reported outcome measures for use in randomised controlled trials in patients with systemic lupus erythematosus: a systematic review
  65. THU0246 DIAGNOSTIC CLUSTER PROFILING OF PATIENTS IN A REAL-WORLD DATA SET WITH SYSTEMIC LUPUS ERYTHEMATOSUS
  66. SAT0213 IMPACT OF FLARES ON HEALTHCARE RESOURCE USAGE AND PROS IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS
  67. THU0271 PERFORMANCE OF THE EULAR/ACR 2019 CLASSIFICATION CRITERIA FOR SYSTEMIC LUPUS ERYTHEMATOSUS IN EARLY DISEASE, ACROSS SEXES AND ETHNICITIES
  68. AB1170 THE IMPACT OF HIGH DISEASE ACTIVITY AS MEASURED BY SLEDAI AND DRUG BURDEN-ON HEALTHCARE UTILIZATION, QUALITY OF LIFE AND WORK PRODUCTIVITY IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS
  69. Identifying a response for the systemic lupus erythematosus disease activity glucocorticoid index (SLEDAI‐2KG)
  70. Effect of TNF‐inhibitor therapy on spinal structural progression in ankylosing spondylitis patients: A systematic review and meta‐analysis
  71. Association between depression and anxiety with skin and musculoskeletal clinical phenotypes in systemic lupus erythematosus
  72. Joint trajectories of disease activity, and physical and mental health-related quality of life in an inception lupus cohort
  73. Assessment of the psychometric properties of patient-reported outcomes of depression and anxiety in systemic lupus erythematosus
  74. Associations among classification criteria items within systemic lupus erythematosus
  75. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus
  76. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus
  77. Association of systemic lupus erythematosus (SLE) genetic susceptibility loci with lupus nephritis in childhood-onset and adult-onset SLE
  78. Drs. Tayer-Shifman and Touma reply
  79. Prevalence and metric of depression and anxiety in systemic lupus erythematosus: A systematic review and meta-analysis
  80. FRI0256 ASSESSING THE PREVALENCE AND USE OF VALIDATED SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY METRICS IN REAL WORLD PRACTICE
  81. FRI0178 CLUSTER PROFILING OF PATIENTS IN A REAL-WORLD DATA SET WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND THEIR ASSOCIATED TREATMENTS
  82. FRI0669 DEPRESSION AND ANXIETY AND THEIR CLINICAL CORRELATES IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
  83. THU0250 EARLY IMPROVEMENT IN SLEDAI-2K RESPONDER INDEX-50 PREDICTS SRI-4 RESPONSE IN A RANDOMIZED PLACEBO-CONTROLLED TRIAL OF USTEKINUMAB (UST) IN SYSTEMIC LUPUS ERYTHEMATOSUS
  84. AB0486 LACK OF CONSISTENT STANDARD OF CARE IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS IN REAL WORLD
  85. FRI0189 POOLED ANALYSIS OF THE REAL-WORLD EFFECTIVENESS OF BELIMUMAB IN TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS USING MULTI-COUNTRY DATA FROM THE OBSERVE STUDIES
  86. Clinical Remission and Low Disease Activity Outcomes Over 10 Years in Systemic Lupus Erythematosus
  87. The Assessment of Anxiety and Depression and its Associated Factors in SLE
  88. Preliminary Definitions for Sacroiliac Joint Pathologies in the OMERACT Juvenile Idiopathic Arthritis Magnetic Resonance Imaging Score (OMERACT JAMRIS-SIJ)
  89. Impact of belimumab on patient-reported outcomes in systemic lupus erythematosus: review of clinical studies
  90. Disease course patterns in systemic lupus erythematosus
  91. How Do Patients With Newly Diagnosed Systemic Lupus Erythematosus Present? A Multicenter Cohort of Early Systemic Lupus Erythematosus to Inform the Development of New Classification Criteria
  92. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study
  93. What is the prevalence of cognitive impairment in lupus and which instruments are used to measure it? A systematic review and meta-analysis
  94. Novel biological therapeutic approaches to cutaneous lupus erythematosus
  95. Canadian Rheumatology Association Recommendations for the Assessment and Monitoring of Systemic Lupus Erythematosus
  96. Measuring Disease Activity and Damage with Validated Metrics: A Systematic Review on Mortality and Damage in Systemic Lupus Erythematosus
  97. Subcutaneous belimumab in the treatment of systemic lupus erythematosus
  98. Psoriatic Arthritis Sonographic Enthesitis Instruments: A Systematic Review of the Literature
  99. Epidemiology and Survival of Systemic Sclerosis-Systemic Lupus Erythematosus Overlap Syndrome
  100. Monophasic Disease Course in Systemic Lupus Erythematosus
  101. FRI0208 Ankylosing spondylitis quality of life: defining minimal clinically important change
  102. THU0423 Epidemiology and survival of systemic sclerosis-systemic lupus erythematosus overlap syndrome
  103. Apoptotic cell–induced AhR activity is required for immunological tolerance and suppression of systemic lupus erythematosus in mice and humans
  104. Identification of a neutrophil-related gene expression signature that is enriched in adult systemic lupus erythematosus patients with active nephritis: Clinical/pathologic associations and etiologic mechanisms
  105. Minimal Clinically Important Difference
  106. A novel lupus activity index accounting for glucocorticoids: SLEDAI-2K glucocorticoid index
  107. Effect of complete or partial proteinuria recovery on long-term outcomes of lupus nephritis
  108. Comparison of the Sensitivity to Change of the 36-Item Short Form Health Survey and the Lupus Quality of Life Measure Using Various Definitions of Minimum Clinically Important Differences in Patients With Active Systemic Lupus Erythematosus
  109. Current and future therapies for SLE: obstacles and recommendations for the development of novel treatments
  110. Comparison of Spot Urine Protein to Creatinine Ratio to 24-Hour Proteinuria to Identify Important Change Over Time in Proteinuria in Lupus
  111. Performance of Screening Tests for Cognitive Impairment in Systemic Lupus Erythematosus
  112. The utility of lupus serology in predicting outcomes of renal transplantation in lupus patients: Systematic literature review and analysis of the Toronto lupus cohort
  113. Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada Study
  114. Reply
  115. Prevalence and associated factors of resting electrocardiogram abnormalities among systemic lupus erythematosus patients without cardiovascular disease
  116. Predictors of Good Long-Term Renal Outcomes in Lupus Nephritis: Results from a Single Lupus Cohort
  117. Risk of Cardiovascular Morbidity in Patients With Psoriatic Arthritis: A Meta-Analysis of Observational Studies
  118. Prevalence and associated factors of low bone mass in adults with systemic lupus erythematosus
  119. Recent advances in the biologic therapy of lupus: the 10 most important areas to look for common pitfalls in clinical trials
  120. Utility of Urinary Protein-Creatinine Ratio and Protein Content in a 24-Hour Urine Collection in Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
  121. Systemic lupus erythematosus
  122. FRI0307 Changes in Urinary Biomarker Levels Can Predict Treatment Responses in Lupus Nephritis
  123. FRI0341 Do Patients with SLE at Onset Differ from Mimickers? A Comparison of Clinical and Serological Manifestations in A Multicenter Cohort To Inform The Development of New Classification Criteria for SLE: Table 1
  124. Canadian Rheumatology Association Meeting, February 17-20, 2016. Introduction, Abstracts, Author Index
  125. Clinical and Demographic Characteristics of Erosion-free and Erosion-present Status in Psoriatic Arthritis in a Cohort Study
  126. Impact of pulmonary disease on patient-reported outcomes and patient-performed functional testing in systemic lupus erythematosus
  127. Utility of untimed single urine protein/creatinine ratio as a substitute for 24-h proteinuria for assessment of proteinuria in systemic lupus erythematosus
  128. SLEDAI-2K Does Not Conceal Worsening in a Particular System When There Is Overall Improvement
  129. OP0091 A Low Density Granulocyte Gene Expression Signature Distinguishes Between Active Patients with and Without Nephritis in Systemic Lupus Erythematosus (SLE)
  130. SAT0404 Spot Urine Protein/Creatinine Ratio is Useful in Screening for Proteinuria but Should Not Substitute 24 hours Urine Collection Sample to Quantify Proteinuria in Lupus
  131. SAT0386 What is the Best Screening Test to Identify Lupus Patients with Cognitive Impairment in an Ambulatory Setting?
  132. DEVELOPING AN IPAD® APPLICATION FOR DATA COLLECTION IN A RHEUMATOLOGY RESEARCH CLINIC
  133. Profile of epratuzumab and its potential in the treatment of systemic lupus erythematosus
  134. OP0042 Do We Know How and When to Stop Immunosuppressants in Lupus Patients?
  135. Time to Recovery from Proteinuria in Patients with Lupus Nephritis Receiving Standard Treatment
  136. Outcome measures in systemic lupus erythematosus
  137. Top 10 Recent Developments in Health-Related Quality of Life in Patients with Systemic Lupus Erythematosus
  138. Development, Sensibility, and Reliability of the Toronto Axial Spondyloarthritis Questionnaire in Inflammatory Bowel Disease
  139. GRAPPA Trainees Symposium 2012: A Report from the GRAPPA 2012 Annual Meeting
  140. THU0197 Time to recovery from proteinuria in lupus nephritis patients receiving standard of care treatment
  141. Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50 Website
  142. Skin Nontuberculous Mycobacterial Infection in Systemic Lupus Erythematosus: An Unusual Skin Infection Mimicking Lupus Vasculitis
  143. Vaccination and auto-immune rheumatic diseases
  144. Systemic lupus erythematosus: an update on current pharmacotherapy and future directions
  145. The Assessment of Disease Activity in Rheumatic Diseases
  146. Development and Assessment of Users’ Satisfaction with the Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50 Website
  147. SLEDAI-2K Responder Index 50 captures 50% improvement in disease activity over 10 years
  148. Development validation and reliability of the Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50
  149. Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index 50: sensitivity to response at 6 and 12 months
  150. Does the change in season affect disease activity in patients with psoriatic arthritis?
  151. Ability of non-fasting and fasting triglycerides to predict coronary artery disease in lupus patients
  152. Seasonal variation in vitamin D levels in psoriatic arthritis patients from different latitudes and its association with clinical outcomes
  153. Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50 Enhances the Ability of SLE Responder Index to Identify Responders in Clinical Trials
  154. Is There an Advantage Over SF-36 with a Quality of Life Measure That Is Specific to Systemic Lupus Erythematosus?
  155. Cross-cultural adaptation and validation of Behçet's disease quality of life questionnaire
  156. Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50: A Reliable Index for Measuring Improvement in Disease Activity
  157. SLEDAI-2K 10 days versus SLEDAI-2K 30 days in a longitudinal evaluation
  158. Development and Initial Validation of the Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index 50
  159. Optimal Frequency of Visits for Patients with Systemic Lupus Erythematosus to Measure Disease Activity Over Time
  160. Mycophenolate Mofetil for Induction Treatment of Lupus Nephritis: A Systematic Review and Metaanalysis
  161. TNF Polymorphisms in Patients with Behçet Disease: A Meta-analysis
  162. SLEDAI-2K for a 30-day window
  163. Successful treatment of cardiac involvement in dermatomyositis with rituximab
  164. Efficacité du rituximab dans le traitement d’une dermatomyosite avec atteinte cardiaque
  165. Long-Delayed Onset of Chest Wall Pain Defining a Patient With SAPHO Syndrome
  166. Oral bisphosphonates in treatment of transient osteoporosis
  167. Longitudinal myelitis in patient with systemic lupus erythematosus, homozygous prothrombin G20210A and heterozygous MTHFR 677T
  168. The use of TNF-α blockers in Cogan’s syndrome
  169. Family history of lymphoma and risk for solid tumors in patients with Sjogren’s syndrome
  170. Topical nonsteroidal anti-inflammatory drugs in the treatment of osteoarthritis
  171. Cardiac sarcoidosis responding to monotherapy with infliximab
  172. Endobronchial stenting for respiratory complications in relapsing polychondritis
  173. Successful treatment of Sjogren's syndrome with rituximab
  174. Successful retreatment with infliximab in patients with prior severe infusion reactions
  175. Response of deep cutaneous vasculitis to infliximab
  176. Fatal streptococcal toxic shock syndrome in a patient with rheumatoid arthritis treated with etanercept